Partners Investment

Partners Investment is one of the older and larger names in Korean venture, and its profile sits at the intersection of biotech and AI software rather than at either pole alone. Headquartered in Seoul and writing $1M-$5M checks into Series A through Series C, the firm is structured to follow Korean companies from product traction into the IPO pipeline that the Korean public markets actively support. That positioning, more than any single thesis statement, explains how it picks deals: the firm wants companies that can credibly reach a KOSDAQ or US listing, and it sizes its involvement accordingly.

The healthcare focus splits between biotech and AI/ML. On the therapeutics side, that means backing platforms and clinical-stage assets where Korean R&D ecosystems have a real edge, particularly oncology, antibodies, and platform biology. On the AI side, the firm leans toward software and ML systems that touch healthcare workflows, diagnostics, and life-sciences tooling rather than pure consumer wellness. The connecting thread is companies with defensible technical depth and a credible path to public-market scale, not lifestyle businesses or thin SaaS wrappers.

Stage discipline is unusually clean for a Korean firm of this size. Partners Investment writes Series A, B, and C checks rather than dabbling at seed, and the $1M-$5M range typically lands it as a meaningful syndicate participant or co-lead rather than a marginal name on the cap table. Geographically, Korea is home base, but the firm regularly co-invests on cross-border rounds where a Korean strategic angle, manufacturing partnership, or Asian commercial expansion is part of the story. Founders outside Korea should expect questions about how Partners Investment’s platform can pull weight in the region, not just whether the firm can wire dollars.

The team is anchored by Korean venture professionals with long tenure in the country’s IPO-driven ecosystem, and the diligence style reflects that. Expect rigorous technical and clinical review on biotech, careful financial modeling on AI businesses, and detailed conversations about path to public markets. The firm has cultivated relationships with Korean investment banks, large pharma partners, and downstream investors that matter when it comes time to raise crossover or pre-IPO rounds, and that network is part of what founders are buying when they accept its capital.

The practical read for founders is that Partners Investment is a strong fit when you have a real Series A or later business and want a Korean institutional partner who will stay through to exit. The firm is less useful for very early-stage founders, for non-AI consumer health plays, or for companies with no plausible Asian commercial story. Engagement style sits between hands-on and arms-length: the firm participates actively in board governance and follow-on financings but does not run the company. Founders who want a Korean anchor on the cap table heading into IPO conversations are exactly the audience this firm is built for, and pitches that ignore the public-market endgame tend to land flat.